Related Experiment Video
Updated: Jul 15, 2026
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
Published on: July 28, 2020
Targeted therapies for soft-tissue sarcomas
William D Tap1, Noah Federman, Fritz C Eilber
1UCLA Sarcoma Program, Division of Hematology/Oncology, Los Angeles, CA 90095-7059, USA. wtap@mednet.ucla.edu
Abstract:
The past several decades have revealed certain challenges that are inherent to soft-tissue sarcomas with regards to devising, testing and setting treatment paradigms for such a rare and heterogeneous malignancy. Despite this, significant advances have been made through the efforts of scientists, clinicians and patients alike. We are now entering a molecular era of cancer and current biotechnology is beginning to unravel the pathogenic enigma of these often devastating tumors. As our understanding of these malignancies improves, so does our list of potential treatment options. The impetus now lies with the medical/scientific community to direct translational research and subsequently the development and clinical testing of novel compounds in a fashion that best serves this unique patient population. To do so, we must continue to integrate the lessons of the past with the resources and promise of the future. This review will outline current areas of therapeutic interest in soft-tissue sarcomas with regard to agents that have reached clinical testing.
Insights
Developing effective treatments for rare soft-tissue sarcomas remains challenging. Advances in molecular biology are improving our understanding and leading to new therapeutic options for these complex cancers.
Area of Science:
- Oncology
- Translational Research
- Molecular Biology
Background:
- Soft-tissue sarcomas are rare and heterogeneous malignancies presenting significant therapeutic challenges.
- Despite difficulties, scientific and clinical efforts have led to notable advances.
- The molecular era of cancer research is beginning to elucidate the underlying biology of these tumors.
Purpose of the Study:
- To review current therapeutic strategies for soft-tissue sarcomas.
- To highlight agents that have progressed to clinical testing.
- To emphasize the need for integrated research approaches.
Main Methods:
- Review of current literature on soft-tissue sarcoma therapeutics.
- Analysis of agents that have undergone clinical trials.
- Discussion of challenges and future directions in treatment development.
Main Results:
- Significant advances have been made in understanding soft-tissue sarcoma biology.
- New therapeutic targets are emerging from molecular research.
- Several novel compounds are currently in clinical testing.
Conclusions:
- Continued integration of past lessons with future promise is crucial for advancing soft-tissue sarcoma treatment.
- Translational research is essential to develop and test novel compounds effectively.
- Improving therapeutic options requires a concerted effort from the scientific and medical community.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:24Modified-Release Drug Delivery Systems: Site-Targeted